Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 9/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.41 |
| ▸ | GPR3 | P46089 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22817198 | 0.92 | SLC6A4 (0.41) | FFAR4GPR84DRD3TRPV1FFAR1 | |
| SCHEMBL22817075 | 0.92 | SLC6A4 (0.41) | FFAR4GPR84DRD3TRPV1FFAR1 | |
| SCHEMBL22817197 | 0.88 | HCRTR2 (0.38) | FFAR4GPR84DRD3FFAR1CYP2C9 | |
| SCHEMBL20204030 | 0.85 | FFAR4 (0.39) | FFAR4GPR3DRD3FFAR1TACR1 | |
| SCHEMBL22817200 | 0.83 | FFAR4 (0.39) | FFAR4GPR84DRD3OPRL1FFAR1 | |
| SCHEMBL21617078 | 0.79 | GPR3 (0.40) | FFAR4GPR3TRPV1CYP2C9SCN5A | |
| SCHEMBL22208778 | 0.79 | FFAR4 (0.40) | FFAR4GPR3TRPV1TACR1KCNH2 | |
| SCHEMBL26794589 | 0.79 | TRPV1 (0.42) | FFAR4GPR3TRPV1KIF11 | |
| SCHEMBL16954442 | 0.76 | TRPV1 (0.42) | FFAR4GPR3TRPV1OPRL1SCN5A | |
| SCHEMBL16954439 | 0.76 | GPR3 (0.40) | GPR3TRPV1KCNH2KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479844-B2 | Ion channel modulators | PRAXIS PRECISION MEDICINES, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| US-20250145629-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2025-05-08 | — | — | US | disclosed |
| US-12145939-B2 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators | PRAXIS PRECISION MEDICINES, INC. (US) | 2024-11-19 | — | — | US | disclosed |
| US-20240043433-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2024-02-08 | — | — | US | disclosed |
| US-11767325-B2 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767325-B2 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767325-B2 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20210403476-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2021-12-30 | — | — | US | disclosed |
| US-20210403476-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2021-12-30 | — | — | US | disclosed |
| CN-113573713-A | Ion channel modulators | 普拉克西斯精密药物股份有限公司 | 2021-10-29 | — | — | CN | disclosed |
| EP-3856193-A1 | ION CHANNEL MODULATORS | Praxis Precision Medicines, Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| US-20210171530-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2021-06-10 | — | — | US | disclosed |
| US-20210171530-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2021-06-10 | — | — | US | disclosed |
| WO-2020069322-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. (US) | 2020-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210403476-A1 | ION CHANNEL MODULATORS | SCN1A, SCN3A, SCN2A | FFAR4 2492/4885GPR84 2364/4885GPR3 722/4885 |
| US-12145939-B2 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators | SCN1A, SCN2A, SCN5A | FFAR4 3146/4885GPR84 2367/4885GPR3 462/4885 |
| US-20250145629-A1 | ION CHANNEL MODULATORS | SCN1A, SCN3A, SCN2A | FFAR4 2492/4885GPR84 2364/4885GPR3 722/4885 |
| US-20240043433-A1 | ION CHANNEL MODULATORS | SCN1A, SCN3A, SCN2A | FFAR4 2492/4885GPR84 2364/4885GPR3 722/4885 |
| US-11767325-B2 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators | SCN1A, SCN2A, SCN5A | FFAR4 3255/4885GPR84 2558/4885GPR3 621/4885 |
| US-20210171530-A1 | ION CHANNEL MODULATORS | SCN1A, SCN3A, SCN2A | FFAR4 2492/4885GPR84 2364/4885GPR3 722/4885 |
| US-12479844-B2 | Ion channel modulators | SCN1A, SCN3A, SCN2A | FFAR4 2492/4885GPR84 2364/4885GPR3 722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.